Rosiglitazone Improves Glucocorticoid Resistance in a Sudden Sensorineural Hearing Loss by Promoting MAP Kinase Phosphatase-1 Expression

Mediators Inflamm. 2019 May 14:2019:7915730. doi: 10.1155/2019/7915730. eCollection 2019.

Abstract

In this study, we investigated the role of MAP kinase phosphatase-1 (MKP-1) and rosiglitazone (RSG) in glucocorticoid resistance and glucocorticoid sensitivity, respectively, using a guinea pig model of lipopolysaccharide- (LPS-) induced sudden sensorineural hearing loss (SSHL). The pigs were divided into control, LPS, LPS+dexamethasone (DEX), LPS+RSG, and LPS+DEX+RSG groups. Their hearing was screened by auditory brainstem response measurement. Immunofluorescence staining was used to identify the location of MKP-1 in the inner ear. The expression levels of MKP-1 and the related proteins in the inner ear were detected using western blotting. The morphological changes in the cochlea were observed via hematoxylin-eosin staining. Severe hearing loss was observed in the LPS group, as opposed to the protection from hearing loss observed in the LPS+DEX+RSG group. A positive correlation was observed between MKP-1 expression levels and protection from hearing loss. RSG and DEX synergistically influenced inner ear inflammation. In conclusion, resistance of LPS-induced SSHL guinea pig models to glucocorticoids may result from impaired MKP-1 function in inner ear tissues, induced by glucocorticoids, impairing the inhibition of inflammation. Our findings present novel targets to develop potential therapeutics to treat inflammatory diseases of the inner ear.

MeSH terms

  • Animals
  • Dexamethasone / pharmacology
  • Dexamethasone / therapeutic use
  • Dual Specificity Phosphatase 1
  • Evoked Potentials, Auditory, Brain Stem / drug effects
  • Glucocorticoids / pharmacology*
  • Glucocorticoids / therapeutic use*
  • Guinea Pigs
  • Hearing / drug effects*
  • Hearing Loss, Sensorineural / chemically induced
  • Hearing Loss, Sensorineural / drug therapy*
  • Lipopolysaccharides / toxicity
  • Male
  • Rosiglitazone / pharmacology*
  • Rosiglitazone / therapeutic use*

Substances

  • Glucocorticoids
  • Lipopolysaccharides
  • Rosiglitazone
  • Dexamethasone
  • Dual Specificity Phosphatase 1